Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Breaks Below 200 Day Moving Average – Here’s Why

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.19 and traded as low as $0.16. Northwest Biotherapeutics shares last traded at $0.1620, with a volume of 18,208,090 shares trading hands.

Northwest Biotherapeutics Price Performance

The company has a market cap of $285.49 million, a price-to-earnings ratio of -0.01 and a beta of -0.62. The business’s 50-day simple moving average is $0.17 and its 200-day simple moving average is $0.19.

Northwest Biotherapeutics (OTCMKTS:NWBO) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.81 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC bought a new stake in Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned approximately 0.07% of Northwest Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 0.04% of the company’s stock.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a biotechnology company focused on developing personalized immunotherapies for cancer. Its technology uses a patient’s own dendritic cells, which are immune cells that can be prepared to recognize and target that individual’s tumor.

The company’s lead product candidate is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also investigated its platform in other solid tumors, including metastatic cancers, although DCVax-L has been the company’s primary clinical development program.

Northwest Biotherapeutics was founded in 1996 and is based in Bethesda, Maryland.